anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Atrial fibrillation (AF) is a stroke risk factor that often remains undetected at hospital admission. Long-term Holter monitoring helps to identify patients with previously unrecognized AF. Asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are elevated in AF in cross-sectional studies. We analyzed ADMA, SDMA, and other L-arginine metabolites to assess their association with AF in the Find-AF trial.
METHODS AND RESULTS: We included 280 patients presenting with acute cerebral ischemia. Patients presenting in sinus rhythm received 7-day Holter-ECG. Biomarkers were quantified by ultra-performance liquid chromatography-tandem mass spectrometry. We also analyzed protein methylation and L-arginine-related metabolites in human induced pluripotent stem cell-derived cardiomyocytes in vitro. ADMA and SDMA were elevated in 44 patients who presented with AF. SDMA, but not ADMA, was significantly elevated in patients newly diagnosed with AF in Holter-ECG as compared with those in sinus rhythm. SDMA plasma concentration >0.571 μmol/L significantly predicted presence of AF in Holter-ECG (area under the curve=0.676 [0.530-0.822]; P=0.029; sensitivity 0.786, specificity 0.572). SDMA levels further increased in patients with AF during the first 24 hours in hospital, and ADMA levels remained stable. In vitro, induced pluripotent stem cell-derived cardiomyocytes showed increased symmetric protein methylation and elevated SDMA during rapid pacing (2.0 Hz versus 0.5 Hz), whereas asymmetric protein methylation and ADMA were unchanged.
CONCLUSIONS: SDMA at admission was significantly elevated in stroke patients presenting with AF and showed a moderate but significant prospective association with previously unrecognized AF. Thus, stroke patients with elevated SDMA concentration at admission may specifically benefit from extended Holter-ECG monitoring.
Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
Hybridization and polyploidy are powerful evolutionary forces, inducing a range of phenotypic outcomes, including non-additive expression, subgenome dominance, deviations in genomic dosage, and transcriptome downsizing. The reasons for these patterns and whether they are universal adaptive responses to genome merging and doubling remain debated. To address this, we develop a thermodynamic model of gene expression based on transcription factor (TF)-promoter binding. Applied to hybridization between species with divergent gene expression levels, cell volumes, or euchromatic ratios, this model distinguishes the effects of hybridization from those of polyploidy. Our results align with empirical observations, suggesting that gene regulation patterns in hybrids and polyploids often stem from the constrained interplay between inherited diverged regulatory networks rather than from subsequent adaptive evolution. In addition, occurrence of certain phenotypic traits depend on specific assumptions about promoter-TF coevolution and their distribution within the hybrid's nucleoplasm, offering new research avenues to understand the underlying mechanisms. In summary, our model explains how the legacy of divergent species directly influences the phenotypic traits of hybrids and allopolyploids.
The present invention discloses a system and method for preparing and delivering various health and longevity compositions. This invention is designed to improve the quality of life and lifespan of mammals. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation; misting; nasal spray; intravenous, IM, and/or sub-cutaneous, injection; suppository; etc. A non-toxic therapeutic anabolic hormone replenishment is combined with rapamycin and cannabidiol. The three compounds work together to improve quality of life and healthy lifespan. Preferred additional included supplements may include metformin, growth hormone, and/or supplemented minerals. A preferred embodiment features low dose continuous supplementation, e.g., to be incorporated with a daily meal. The process of the present invention delivers an orally ingested substance, e.g., a snack, a human food supplement, an animal treat, etc., that contains the active compounds to be absorbed by the digestive system or delivered into the bloodstream.
PURPOSE:An antitumor agent having high effects on reduction in number of tumor cells, prolongation of life, inhibition of tumor multiplication, etc. in tumor of animal and human, containing a compound such as sodium 2-(2,6- dichloroanilino)-phenylacetate, etc. as an active ingredient. CONSTITUTION:An antitumor agent containing a compound shown by the formu la (R is H, Cl, OH, or OCOCH3), such as sodium 2-(2,6-dichloroanilino)- phenylacetate as an active ingredient. A content of the active ingredient during pharmaceutical manufacturing is generally 0.01-100wt%, preferably 0.05-80wt%. The dosage form includes powder, fine granule, granule, etc. as oral administration, ampule of injection, bottle, etc. as parenteral administra tion, and form of suppository and ointment may be used.
Compositions for the treatment of uric acid deficiency are disclosed. The compositions generally comprise either a precursor or derivative of uric acid, which, when administered to a patient, will result in a raising of the uric acid levels in that patient. The compositions can optionally comprise one or more additional active ingredients such as antioxidants, glutathione precursors, or inhibitors of NO synthase or homocysteine. Methods for raising uric acid levels in a patient are also disclosed. These methods are useful for in the treatment of various illnesses, such as cancer, infectious disease, Alzheimer disease and neurodegenerative diseases. Use of improved solutions comprising the present compositions in organ preservation is also disclosed.
People with CKD 5 (eGFR \<15), but not on dialysis. They will have body composition measured, and eGFR measured.
FIELD: medicine, therapy. SUBSTANCE: the main components of agent that is used for wounds treatment are balsamic substance and gel-forming base. Bornyl- or isobornyl acetate is used as a balsamic substance at the following ratio, wt.-%: bornyl - or isobornyl acetate 10.0-15.0, and gel-forming base 85.0-90.0. Agent accelerates necrotic tissues rejection, decreases healing time and stimulates development of young granulation tissue, promotes formation of epithelial layer. EFFECT: enhanced effectiveness of an agent. 1 tbl
PURPOSE: A composition containing Berchemia racemosa var. magna extract and a cosmetic composition containing the same are provided to suppress tyrosinase activity and remove free radical. CONSTITUTION: A cosmetic composition for skin whitening contains Berchemia racemosa var. magna extract as an active ingredient. The extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. The Berchemia racemosa var. magna extract includes 4-n-butylresorcinol of chemical formula 1, quercetin of chemical formula 2, or kaempferol of chemical formula 3. The cosmetic composition is manufactured in the form of a skin softener, astringent, massage cream, essence, pack, patch, or gel.
PURPOSE:To obtain a dental composition for sealing pit and fissure, by homogeneously mixing calcium hydrogen phosphate with equimolar amount of calcium carbonate, pulverizing the mixture after baking and adding a fluorine compound and an adjuvant to the obtained main component. CONSTITUTION:Calcium hydrogen phosphate is homogeneously mixed with equimolar amount of calcium carbonate, baked at 1,400-1,600 deg.C and crushed. The obtained powder for main component is added with 0.01-2wt.% of a fluorine compound (e.g. aluminum fluoride) and an adjuvant (e.g. water, an aqueous solution of an organic acid or an aqueous solution of an inorganic acid) to obtain the objective dental composition, especially a composition effective in preventing the cariogenesis of juvenile by sealing the pit and fissure on the occlusal surface of the tooth. The composition is preferably further compounded with one or more components selected from hydroxyapatite, tricalcium alpha-phosphate, tricalcium beta-phosphate and calcium hydrogen phosphate dihydrate.
PURPOSE:To provide a base for external application to skin, containing phospholipid and catechin, having excellent age resistance and thermal stability, free from deterioration such as discoloration and giving good feeling to the skin. CONSTITUTION:The objective base for external application contains 0.5-6wt% phospholipid and 0.01-0.1% catechin. Since phospholipid is relatively similar to the component of skin, it is suitable as a raw material for skin cosmetic. The age resistance and thermal stability of phospholipid can be improved by the combined use with catechin. The phospholipid is e.g. phosphatidyl choline (lecithin), etc., however, it is preferable to use soybean phospholipid (soya lecithin) or yolk phospholipid (yolk lecithin) for practical purpose. A drug preparation having higher stability can be produced by using a pyrogallol-type catechin having OH group at the 5'-site compared with a catechol-type catechin free from OH group at the 5'-site.
Objective Although magnetic resonance imaging (MRI) is the gold standard for evaluating abnormal myocardial fibrosis and extracellular volume (ECV) of the left ventricular myocardium (LVM), a similar evaluation has recently become possible using computed tomography (CT). In this study, we investigated the diagnostic accuracy of a new 256-row multidetector CT with a low tube-voltage single energy scan and deep-learning-image reconstruction (DLIR) in detecting abnormal late enhancement (LE) in LVM. Methods We evaluated the diagnostic performance of CT for detecting LE in LVM and compared the results with those of MRI as a reference. We also measured the ECV of the LVM on CT and compared the results with those on MRI. Materials We analyzed 50 consecutive patients who underwent cardiac CT, including a late-phase scan and MRI, within three months of suspected cardiomyopathy. All patients underwent 256-slice CT (Revolution APEX; GE Healthcare, Waukesha, USA) with a low tube-voltage (70 kV) single energy scan and DLIR for a late-phase scan. Results In patient- and segment-based analyses, the sensitivity, specificity, and accuracy of detection of LE on CT were 94% and 85%, 100% and 95%, and 96% and 93%, respectively. The ECV of LVM per patient on CT and MRI was 33.0±6.2% and 35.9±6.1%, respectively. These findings were extremely strongly correlated, with a correlation coefficient of 0.87 (p<0.0001). The effective radiation dose on late-phase scanning was 2.4±0.9 mSv. Conclusion The diagnostic performance of 256-row multislice CT with a low tube voltage and DLIR for detecting LE and measuring ECV in LVM is credible.
Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro "bullets." A debriefing followed.
Weight loss compositions and systems are disclosed that may include various combinations of essential oils and other components, which may be effective in promoting weight loss. Some implementations may include a fat blocker, a filler component, an insulin sensitizer, and a fat growth suppressant. In some instances, the fat blocker may include a carotenoid. In other instances, the fat blocker may be selected from the group consisting of fucoxanthin and punicic acid. A weight loss composition may include a first component and a second component, wherein the combination of the first and second components may be effective in promoting weight loss. The first element may include a fat blocker, a filler component, and a first insulin sensitizer. The second element may comprise a fat growth suppressant and a second insulin sensitizer.
### Pregnancy Category C

Furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits at 2, 4 and 8 times the maximal recommended human dose. There are no adequate and well-controlled studies in pregnant women. Furosemide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Treatment during pregnancy requires monitoring of fetal growth because of the potential for higher birth weights.

The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits.

Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day). In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate fetal lethality that can precede maternal deaths.

The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses derived from the treated dams as compared with the incidence in fetuses from the control group.
Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
The invention provides a wound escherichia (Pseudomonas vulgaris) H2-1 and a method for preparing carotenoid degrading enzyme by using the same. The strain H2-1 is preserved in China center for type culture Collection with the preservation number of CCTCC NO: M20211250. Under suitable culture conditions, the strain H2-1 can ferment mannitol to prepare the carotenoid degrading enzyme. The beta-carotene is degraded by the carotenoid degrading enzyme to obtain the beta-damascenone, thereby providing a new way for the production of the beta-damascenone. The carotenoid degradation enzyme crude enzyme solution prepared by fermenting mannitol by the escherichia wound disclosed by the invention has the carotenoid degradation efficiency of over 75%, and the enzyme has the advantages of short production period, low cost, high substrate degradation efficiency, simple culture method and the like, and has a wide application prospect. Before the application, no report shows that the Escherichia vulnificus can be used for preparing carotenoid degrading enzyme, and the application opens up a new way for the application of the Escherichia vulnificus.
NEW MATERIAL:An oxazolium compound I (R1-R3 are lower to medium-length alkyl; X is anion). EXAMPLE:2-[ ( N-methyl-4-ethoxycarbonylanilino )vinyl ]-3,4-dimethyl-oxazolium iodide. USE:Cosmetics and skin-treating agents. Low toxicity. Characterized by an alkoxycarbonyl group at the para position of a phenyl group. PROCESS:For example, a 3-alkyl-2,4-dimethyloxazolium compound II and a 4-alkoxycarbonyl-N-alkylaniline III are thermally reacted with orthoformic acid ester in the absence of a solvent or in a solvent such as an alcohol to give the compound I.
The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer. Taken together, our data suggest a complex binding mode in which the compounds bind NP specifically in stoichiometric fashion inducing the formation of an NP oligomer without obstructing the RNA binding pocket or interfering with the native NP homo-oligomerization.
OBJECTIVE: To determine the association between sonographically measured abdominal wall thickness (AWT) and birth weight of fetuses of pregnant women with diabetes.
METHODS: This retrospective study included 185 pregnant women who presented to a level I perinatal centre between January 2021 and December 2022. All mothers had diabetes, and were divided into the following subgroups: diet-controlled gestational diabetes mellitus; insulin-dependent gestational diabetes mellitus; type 1 diabetes mellitus; and type 2 diabetes mellitus. At the time of admission, gestational age varied between 29 + 2 and 41 + 2 weeks (+days) of gestation. Weight estimation was performed routinely using the Hadlock I formula. Fetal AWT was determined retrospectively at the same axial level as used for the measurement of abdominal circumference. Only women with a sonographic fetal weight estimation within 5 days before delivery were included.
RESULTS: For the whole cohort, a moderate positive correlation was found between fetal AWT and estimated fetal weight (r = 0.411, p < 0.001), a moderate correlation was found between fetal AWT and birth weight (r = 0.493, p < 0.001), a weak correlation was found between fetal AWT and body length (r = 0.365, p < 0.001), and a weak correlation was found between fetal AWT and body length percentile (r = 0.276, p < 0.001). No strong differences in parameters were found between the diabetes subgroups. Receiver operating characteristic (ROC) curve analysis was performed to identify newborns with birth weight > 4000 g (macrosomia) and birth weight > 90th percentile according to Voigt in the group with gestational age > 37 weeks. ROC curve analysis was performed to identify newborns with birth weight > 90th percentile in the whole cohort. AWT and sonographically estimated fetal weight were included in the calculation. The combination of AWT and estimated fetal weight only led to a marginal improvement compared with estimated fetal weight alone for predicting newborns with birth weight > 4000 g in the group with gestational age > 37 weeks [area under the curve (AUC) 0.857 vs 0.871], and for predicting newborns with birth weight > 90th percentile in the group with gestational age > 37 weeks (AUC 0.840 vs 0.846) and in the whole cohort (AUC 0.816 vs 0.826).
CONCLUSION: A sonographically measured AWT of 7.1 mm in fetuses of diabetic mothers is predictive of birth weight > 90th percentile with sensitivity of 61 %, specificity of 85 %, and AUC of 0.748. ROC curve analysis showed that estimated fetal weight determined by ultrasound (using Hadlock formula I) seems to be slightly superior for the identification of macrosomic fetuses with birth weight > 90th percentile. A threshold value for estimated fetal weight of 3774 g had sensitivity of 70 %, specificity of 86 %, and AUC of 0.816. The combination of AWT and estimated fetal weight in a single formula only yielded a marginal improvement in accuracy compared with the use of estimated fetal weight alone.
Neurogenic bladder (NB) is a significant complication that often occurs after spinal cord injury. It results from urinary dysfunction caused by the injury, disrupting the normal neural control of the bladder and urethra. Symptoms of NB can include urinary frequency, urgency, incontinence, and retention, all of which can greatly impact the quality of life of affected individuals. While there are articles and reviews on NB, fewer specifically address NB following spinal cord injury. This study examined 1095 publications from January 1, 2000, to March 27, 2024, in the Web of Science core database using bibliometric software like VOSviewer, CiteSpace, and Bibliometrics. The analysis revealed an increasing trend in the number of publications, with the United States and China leading in research output. Professor Jeremy B. Myers from the University of Utah had the highest number of publications, while the University of Michigan and the University of Pittsburgh were the institutions with the most publications. The journal Neurourology and Urodynamics had the highest number of articles, and common keywords included management, quality of life, and dysfunction, highlighting key areas of focus for scholars.
Arm 4 will not receive any study treatment. Subjects will undergo surgery on day 0 and follow a preoperative (Day 0) and postoperative blood (Day 30) and tissue (Day 0) sampling schedule.
In a single dose study of Palynziq in adult patients with PKU, two patients receiving concomitant injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced a hypersensitivity reaction. One of the two patients experienced a hypersensitivity reaction on day 15 after a single Palynziq dosage of 0.67 mg within 15 minutes following medroxyprogesterone acetate injectable suspension, and subsequently experienced anaphylaxis on day 89 within 30 minutes after the next dose of medroxyprogesterone acetate injectable suspension. The other patient experienced a hypersensitivity reaction on day 40 after a single Palynziq dosage of 0.08 mg within 10 minutes following medroxyprogesterone acetate injectable suspension. Both patients had high anti‑PEG IgG antibody titers at or around the time of the hypersensitivity reactions. 

In Palynziq clinical trials, the majority of patients developed anti‑PEG IgM and IgG antibodies after treatment with Palynziq [see Adverse Reactions (6.2)]. The clinical effects of concomitant treatment with different PEGylated products is unknown. Monitor patients treated with Palynziq and concomitantly with other PEGylated products for hypersensitivity reactions including anaphylaxis.
Colonic motility plays a vital role in maintaining proper digestive function. The rhythmic contractions and relaxations facilitate various types of motor functions that generate both propulsive and non-propulsive motility modes which in turn generate shear stresses on the epithelial surface. However, the interplay between colonic mucus, shear stress, and epithelium remains poorly characterized. Here, we present a colonic computational model that describes the potential roles of mucus and shear stress in both homeostasis and ulcerative colitis (UC). Our model integrates several key features, including the properties of the mucus bilayer and faeces, intraluminal pressure, and crypt characteristics to predict the time-space mosaic of shear stress. We show that the mucus thickness which could vary based on the severity of UC, may significantly reduce the amount of shear stress applied to the colonic crypts and effect faecal velocity. Our model also reveals an important spatial shear stress variance in homeostatic colonic crypts that suggests shear stress may have a modulatory role in epithelial cell migration, differentiation, apoptosis, and immune surveillance. Together, our study uncovers the rather neglected roles of mucus and shear stress in intestinal cellular processes during homeostasis and inflammation.